Baird analyst Mark Marcon upgraded HealthEquity to Outperform from Neutral with a price target of $87, up from $79.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HQY:
- UPDATE: Conduent’s BenefitWallet HSA Portfolio Moving to HealthEquity
- Conduent’s BenefitWallet HSA portfolio moving to HealthEquity
- HealthEquity management to meet virtually with Oppenheimer
- HealthEquity price target raised to $72 from $71 at Deutsche Bank
- HealthEquity price target raised to $85 from $80 at Barrington